Skip to main content
. 2012 Sep 20;7(9):e45587. doi: 10.1371/journal.pone.0045587

Figure 3. Dyskinesia.

Figure 3

A. Dyskinesia time course. At no time during the 6 h observation period did UWA-101 (1, 3, 6, 10 mg/kg) exacerbate the severity of dyskinesia when compared to L-DOPA/ vehicle treatment (P>0.05). Each time point represents the cumulated dyskinesia scores for every 5 min observation period during the preceding 60 min. The maximal possible score (most severe disability) was 24. On the y-axis, mild = 6, moderate = 12, marked = 18, severe = 24. B. Peak dose dyskinesia. UWA-101 (1, 3, 6, 10 mg/kg) in combination with L-DOPA did not exacerbate the severity of peak dose dyskinesia (sum of dyskinesia score for every 5 min observation period from 80–140 min following treatment, during which dyskinesia severity was maximal) when compared to L-DOPA/ vehicle treatment (P>0.05). Median peak dose dyskinesia severity was moderate – marked in each treatment group. The maximal possible score (most severe disability) was 24. On the y-axis, mild = 6, moderate = 12, marked = 18, severe = 24. Data are expressed as the median (A) and as the median with individual scores (B). ns: not significant.